logo-loader
viewValeo Pharma Inc.

Valeo Pharma closes oversubscribed bought deal bringing in 6.9 million to treasury

Valeo Pharma (CSE: VPH) CEO Steve Saviuk joined Steve Darling from Proactive Vancouver with news the company has closed its previously announced bought deal offering and along with the exercise in full of the Underwriters’ over-allotment option of 750,000 additional Units, the company has topped up the treasury with 6.9 million dollars.

Saviuk shares with Proactive where the capital is expected to be deployed and he also shares his thoughts on the approval of the immune system boosting product Hesperco from Health Canada. 

Quick facts: Valeo Pharma Inc.

Price: 1.4 CAD

CSE:VPH
Market: CSE
Market Cap: $81.3 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex's drug REQORSA in cold storage, ready for upcoming combination trials

  Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive it has met the necessary specifications and passed the final release tests for its first manufacturing run of REQORSA immunogene therapy in advance of non-small cell lung cancer (NSCLC) clinical trials. Varner says the...

2 hours, 24 minutes ago

2 min read